



m3780n

DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration
SOUTHWEST REGION

Office of the Regional
Food and Drug Director
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982
TELEPHONE: 214-655-8100
FACSIMILE: 214-655-8130

May 17, 2000

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

00-SWR-WL-59/8

Lynn Pickering
Imaging Services Manager
Colorado Plains Medical Center
DBA: Colorado Plains MC, Inc.
1000 Lincoln Street
Fort Morgan, CO 80701

RE: Inspection ID - 1130680009

Dear Lynn Pickering,

On May 1, 2000 a representative of the State of Colorado, acting in behalf of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed a serious regulatory problem involving the mammography at your facility.

The Mammography Quality Standards Act of 1992 requires your facility to meet specific standards. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 and level 2 findings at your facility:

Level 1: The phantom QC records were missing for 9 weeks for unit 1, General Electric Co. (GE Medical Systems).

Level 1: The processor QC records were missing 14 out of 14 days of operation in month 12/1999. The processor QC records missing 100%, for processor 1, Kodak, X-OMAT.

Level 1: The processor QC records were missing 14 consecutive days for processor 1, Kodak, X-OMAT.

Level 1: The mammograms were processed in processor 1, Kodak, X-OMAT, when it was out of limits on 24 days.

Level 2: 3 of 5 random reports reviewed did not contain an assessment category for site.

Level 2: Corrective action for a failing image score (before further exams) was not documented for unit 1, General Electric Co. (GE Medical Systems).

Level 2: Corrective actions for processor QC failures were not documented at least once for processor 1, Kodak, X-OMAT.

The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection.

Level 1 findings may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility. They represent a serious violation of the law, which may result in FDA taking regulatory action without further notice. These actions include, but are not limited to:

- Placing your facility under a Directed Plan of Correction.
- Charging your facility for the cost of on-site monitoring.
- Assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards.
- Suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. You are required to respond to this office in writing within fifteen (15) working days from receipt of this letter. Please address the following:

- The specific steps you have taken to correct all of the violations noted in this letter.
- Each step your facility is taking to prevent the recurrence of similar violations.
- Equipment settings (including technique factors), raw test data, and calculated final results where appropriate.
- Sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to:
Deborah M. McGee, Radiation Specialist
Food and Drug Administration
7920 Elmbrook Drive, Suite 102
Dallas, TX 75247-4982

Page 3
May 17, 2000

This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact Ms. McGee at (214) 655-8100, extension 138.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Michael Chappell". The signature is fluid and cursive, with a large initial "M" and a long, sweeping tail.

for Michael Chappell
Acting Regional Food and Drug Director